Recent Press Releases

Cummings Releases Memos Detailing Internal Corporate Documents on Skyrocketing Drug Prices

Cummings Releases Memos Detailing Internal Corporate Documents on Skyrocketing Drug Prices Email from Martin Shkreli:"$1 bn here we come" Washington, D.C. (Feb. 2, 2016)—Today, Rep....

Sun Pharma launches Imatinib Mesylate in USA

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any...

Independent Baylor University Study Showcases Economic Impact of Allergan on Waco

Independent Baylor University Study Showcases Economic Impact of Allergan on Waco WACO, Texas, Jan. 29, 2016 /PRNewswire/ -- A new, independent study from the Baylor University Center for Business...

FDA approves first drug to show survival benefit in liposarcoma

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be...

Gilead's John C. Martin, PhD to Assume Role of Executive Chairman of the Board; John F. Milligan, PhD to Be Appointed Chief Executive Officer and Director

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that, effective March 10, 2016, current Chairman and CEO John C. Martin, PhD will assume the role of...

Gilead's John C. Martin, PhD to Assume Role of Executive Chairman of the Board; John F. Milligan, PhD to Be Appointed Chief Executive Officer and Director

FOSTER CITY, Calif.--()--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that, effective March 10, 2016, current Chairman and CEO John C. Martin, PhD will assume the role of...

Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results

Increases Fourth Quarter Revenues 1% to $4.3 Billion, 4% for Full Year to $16.6 Billion Posts Fourth Quarter GAAP Loss Per Share of $0.08 and Non-GAAP EPS of $0.38 Achieves Significant...

Celgene Reports Fourth Quarter and Full Year 2015 Operating and Financial Results

Data from at Least 18 Phase III Trials Expected from Mid-2016 Through Mid-2018 2016 Guidance for Total Net Product Sales, REVLIMID® Net Sales and Diluted EPS SUMMIT, N.J.--(BUSINESS WIRE)--...

Roche reports strong results in 2015

Basel, 28 January 2016 Roche reports strong results in 2015 Group sales increased by 5%1 at constant exchange rates, 1% in Swiss francs Pharmaceuticals Division sales up 5%, driven by oncology...

Biogen 2015 Revenues Increase 11% to $10.8 Billion

2015 Non-GAAP Diluted EPS Rise 23%, GAAP Diluted EPS Rise 24% Company advances leading neuroscience portfolio including programs in Alzheimer's disease, spinal muscular atrophy, and a repair...

Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations

Strong growth (cc) in full year sales, core operating income and core EPS[2] Net sales up 5% (cc) and core operating income up 10% (cc) Core operating income margin up 1.3 percentage points...

Johnson & Johnson Reports 2015 Fourth-Quarter Results

2015 Fourth-Quarter Sales of $17.8 Billion decreased 2.4%; EPS was $1.15 2015 Full-Year Sales of $70.1 Billion decreased 5.7%, Full-Year EPS was $5.48 Adjusted 2015 Fourth-Quarter EPS was $1.44, an...

Novo Nordisk Launches Tresiba® (insulin degludec injection 200 Units/mL) in the United States

Long-acting Tresiba® U-200 now available for adults living with diabetes PLAINSBORO, N.J., Jan. 26, 2016 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the...

NICE issues final guidance recommending 7 drugs for rheumatoid arthritis

NICE issues final guidance recommending 7 drugs for rheumatoid arthritis 26 January 2016 In final updated guidance published today NICE recommends a number of drugs called biological disease...

Bristol-Myers Squibb's Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1

Opdivo + Yervoy Regimen now indicated for unresectable or metastatic melanoma patients, regardless of BRAF mutational status, based on accelerated approval1 Demonstrated significantly superior...

Valeant Provides Update On J. Michael Pearson

LAVAL, Quebec, Jan. 25, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today released a memo sent to Valeant employees from J. Michael Pearson, who is...

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication...

Shire Completes Acquisition of Dyax

Shire Completes Acquisition of Dyax LEXINGTON, Massachusetts, January 22, 2016 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that it has completed its acquisition of Dyax Corp. (...

FDA Approves New Kyprolis® (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma

Pivotal Head-To-Head ENDEAVOR Study Shows Kyprolis and Dexamethasone Doubled Progression-Free Survival Versus Velcade® (Bortezomib) and Dexamethasone Kyprolis Label Expansion Represents Critical...

U.S. FDA Approves BOTOX® (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults

- BOTOX® is the First and Only FDA-Approved Neurotoxin Treatment for Both Upper and Lower Limb Spasticity - DUBLIN, Jan. 22, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global...